Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.M. Lee.
Hepatitis B virus infection.
N Engl J Med, 337 (1997), pp. 1733-1745
[2.]
J.H. Hoofnagle, A.M. di Bisceglie.
The treatment of chronic viral hepatitis.
N Engl J Med, 336 (1997), pp. 347-356
[3.]
P.M. Rosenberg, J.L. Dienstag.
Therapy with nucleoside analogues for hepatitis B virus infection.
Clin Liver Dis, 3 (1999), pp. 349-360
[4.]
A.S. Lok, E.J. Heathcote, J.H. Hoofnagle.
Management of hepatitis B: summary of a workshop.
Gastroenterology, 120 (2001), pp. 1828-1853
[5.]
J.L. Dienstag, E.R. Schiff, T.L. Wight, et al.
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med, 341 (1999), pp. 1256-1263
[6.]
Y-F Liaw, N.W.Y. Leung, T-T Chang, R. Guan, D-I Tai, K-Y Ng, et al.
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.
Gastroenterology, 119 (2000), pp. 172-180
[7.]
N.C. Tassopoulos, R. Volpes, G. Pastore, et al.
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.
Hepatology, 29 (1999), pp. 889-896
[8.]
L.J. Stuyver, S.A Locarnini, A. Lok, et al.
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.
Hepatology, 33 (2001), pp. 751-757
[9.]
F. Zoulim, C. Trepo.
Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.
J Hepatol, 29 (1999), pp. 151-168
[10.]
P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, M. Siffman, et al.
Adefovir dipivoxil for the treatment of patients hepatitis B e antigen positive chronic hepatitis B.
N Engl J Med, 348 (2003), pp. 808-816
[11.]
S. Hadziyannis, N. Tassopoulos, J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, et al.
Adefovir dipivoxil for the treatment of patients hepatitis B e antigen negative chronic hepatitis B.
N Engl J Med, 348 (2003), pp. 800-807
[12.]
M. Peters, H.W. Hann, P. Martin, E. Heathcote, P. Buggisch, A.E. Moorat, et al.
Adefovir dipivoxil alone and in combination with lamivudine suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis.
Hepatology, 36 (2002), pp. 374A
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
